Wexford Capital LP Makes New Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX)

Wexford Capital LP purchased a new position in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 20,000 shares of the company's stock, valued at approximately $348,000.

A number of other hedge funds also recently bought and sold shares of BCAX. Spire Wealth Management purchased a new position in shares of Bicara Therapeutics in the fourth quarter valued at approximately $31,000. BNP Paribas Financial Markets acquired a new stake in shares of Bicara Therapeutics in the fourth quarter valued at approximately $32,000. Legal & General Group Plc acquired a new stake in shares of Bicara Therapeutics in the fourth quarter valued at approximately $33,000. Summit Investment Advisors Inc. acquired a new stake in shares of Bicara Therapeutics in the fourth quarter valued at approximately $35,000. Finally, Virtus ETF Advisers LLC acquired a new stake in shares of Bicara Therapeutics in the fourth quarter valued at approximately $69,000.

Analyst Ratings Changes

BCAX has been the subject of several recent research reports. Stifel Nicolaus set a $48.00 price target on Bicara Therapeutics in a report on Thursday, March 27th. HC Wainwright cut their target price on Bicara Therapeutics from $44.00 to $41.00 and set a "buy" rating for the company in a research note on Friday. Wedbush reissued an "outperform" rating and set a $31.00 target price on shares of Bicara Therapeutics in a research note on Thursday, March 27th. Cantor Fitzgerald reissued an "overweight" rating and set a $13.01 target price on shares of Bicara Therapeutics in a research note on Thursday, March 13th. Finally, Wells Fargo & Company initiated coverage on Bicara Therapeutics in a research note on Thursday, April 17th. They set an "underweight" rating and a $8.00 target price for the company. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $32.00.

Bicara Therapeutics Stock Performance

BCAX opened at $15.21 on Tuesday. Bicara Therapeutics Inc. has a 52 week low of $8.91 and a 52 week high of $28.09. The business has a fifty day simple moving average of $12.85 and a 200-day simple moving average of $15.13.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.28). On average, equities analysts forecast that Bicara Therapeutics Inc. will post -2.59 EPS for the current year.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.